Plural 1,3-diazine Rings Patents (Class 544/296)
-
Publication number: 20110039871Abstract: The present invention relates to a novel intermediate useful in the preparation of bosentan and to processes for the preparation of said intermediate and bosentan. The invention further relates to compositions comprising bosentan prepared according to the processes of the invention and their use in the treatment of endothelin-receptor mediated disorders.Type: ApplicationFiled: February 6, 2009Publication date: February 17, 2011Inventors: Abhay Gaitonde, Bindu Manojkumar, Sandeep Mekde, Vikas Padalkar, Hemant Mande
-
Publication number: 20110039693Abstract: The present invention relates to pyrimidin-4-ylmethyl-sulfonamides of formula (I) wherein Ra, n, R, A, Y and Het are as defined in the claims and to the N-oxides, and salts thereof and their use for combating harmful fungi, and also to compositions and seed comprising at least one such compound. The invention also relates to a process for preparing these compounds.Type: ApplicationFiled: February 10, 2009Publication date: February 17, 2011Applicant: BASF SEInventors: Jan Klaas Lohmann, Alice Glaettu, Wassilios Grammenos, Jurith Montag, Bernd Mueller, Marianna Vrettou-Schultes, Jens Renner, Sarah Ulmschneider, Michael Rack, Jochen Dietz
-
Publication number: 20110028501Abstract: Substituted cyclopropyl compounds of formula (I) are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.Type: ApplicationFiled: March 26, 2009Publication date: February 3, 2011Inventors: Harold B Wood, Jason W. Szewczyk, Yong Huang, Alan D. Adams
-
Publication number: 20110023754Abstract: Pigment of formula wherein R1 is CONR4R5 or C(?NR6)NR7R8, R2, R3, R4 and R5 are each independently of the others H, C1-C5alkyl, or phenyl which is unsubstituted or substituted from 1 to 5 times by C1-C5alkyl or by halogen, R6 is phenyl which is unsubstituted or substituted from 1 to 4 times by C1-C5alkyl or by halogen, R7 is H or C1-C5alkyl, and R8 is a direct bond or a carbonyl bridge to R6, which pigment consists of primary particles the average aspect ratio of which is from 4 to 1, preferably from 3.5 to 1, especially from 3 to 1, and for the ellipses equivalent to the contours of the primary particles on a two-dimensional electron microscopic image have an average numerical eccentricity ? of from 0 to 0.80, the numerical eccentricity ? being defined as (formula), wherein a is the semimajor axis and b is the semiminor axis of the equivalent ellipse. That pigment preferably has a narrow particle size distribution and is, as are analogous pigments, prepared by a novel process.Type: ApplicationFiled: December 8, 2008Publication date: February 3, 2011Applicant: BASF SEInventors: Rudiger Hainz, Jean Allaz, Didier Schroeder
-
Publication number: 20110021547Abstract: Described is a highly stable crystalline form of bosentan having a water content in the range of about 3-4% by weight, based on the total weight of the bosentan, (bosentan crystalline form A5), a process for preparation thereof, and pharmaceutical compositions comprising the bosentan crystalline form A5. Provided also herein is a bosentan impurity, p-tert-butyl-N[6-hydroxy-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide (deshydroxyethyl bosentan impurity), and process for preparing and isolating thereof. Further provided are highly pure bosentan or a pharmaceutically acceptable salt thereof substantially free of deshydroxyethyl bosentan and bosentan dimer impurities, process for the preparation thereof, and pharmaceutical compositions comprising solid particles of highly pure bosentan or a pharmaceutically acceptable salt thereof, wherein 90 volume-percent of the particles (D90) have a size of less than about 300 microns.Type: ApplicationFiled: January 22, 2009Publication date: January 27, 2011Applicant: ACTAVIS GROUP PTC EHFInventors: Girish Dixit, Nandkumar Gaikwad, Hima Prasad Naidu, Nitin Sharadchandra Pradhan, Jon Valgeirsson
-
Publication number: 20110015394Abstract: The present invention relates to alkaline earth metal salts of bosentan, anyhdrous bosentan, polymorphic forms thereof, amorphous bosentan and processes for preparing them. The present invention further relates to a process for the preparation of bosentan and its pharmaceutically acceptable salts.Type: ApplicationFiled: January 2, 2009Publication date: January 20, 2011Applicant: CIPLA LIMITEDInventors: Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan, Manjinder Singh Phull, Ashwini Amol Sawant
-
Publication number: 20110014291Abstract: Disclosed herein are novel polymorphic forms of bosentan, processes for preparation, pharmaceutical compositions, and method of treating thereof.Type: ApplicationFiled: October 13, 2008Publication date: January 20, 2011Applicant: ACTAVIS GROUP PTC EHFInventors: Girish Dixit, Nandkumar Gaikwad, Hima Prasad Naidu, Nitin Sharadchandra Pradhan, Jon Valgeirsson
-
Patent number: 7868012Abstract: The invention relates to novel sulfamic acid amides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.Type: GrantFiled: November 11, 2005Date of Patent: January 11, 2011Assignee: Actelion Pharmaceuticals, Ltd.Inventors: Martin Bolli, Christoph Boss, Martine Clozel, Walter Fischli, Thomas Weller
-
Publication number: 20100331352Abstract: The present invention relates to novel crystalline forms of bosentan and processes for their preparation. Further, the invention relates to pharmaceutical compositions comprising said crystalline forms and use of said compositions in the treatment of patients suffering from endothelin receptor mediated disorders, for example, cardiovascular disorders such as hypertension, pulmonary hypertension, ischemia, vasospasm and angina pectoris.Type: ApplicationFiled: October 24, 2008Publication date: December 30, 2010Inventor: Abhay Gaitonde
-
Publication number: 20100311750Abstract: The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.Type: ApplicationFiled: December 1, 2008Publication date: December 9, 2010Inventors: Muneto Mogi, Toshio Kawanami, Ken Yamada, Kayo Yasoshima, Hidetomo Imase, Takahiro Miyake, Osamu Ohmori
-
Publication number: 20100298295Abstract: The invention provides novel pyrimidine derivatives of formula (1) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or anaplastic lymphoma kinase (ALK).Type: ApplicationFiled: August 27, 2008Publication date: November 25, 2010Applicant: IRM LLCInventors: Thomas H. Marsilje, Wenshuo Lu, Bei Chen, Xiaohui He, Badry Bursulaya, Christian Cho-Hua Lee, Nathanael S. Gray
-
Publication number: 20100297009Abstract: Self-assembled, closed and hollow chemical multimer structures having a dodecahedral morphology, composed of chemical monomers having a structurally symmetric core which possess a 5-fold rotational symmetry, are provided. Also provided are methods of creating such chemical monomers, methods of creating such chemical multimer structures and compositions comprising these chemical multimer structures. Also provided are uses of these chemical multimer structures in applications such as drug delivery, imaging, immunization, formation of plastic crystals and nanoparticle matrices and other medical and material science applications.Type: ApplicationFiled: March 13, 2008Publication date: November 25, 2010Inventors: Arthur Olson, Ehud Keinan
-
Publication number: 20100298562Abstract: The present invention relates to nonlinear oligopyridazine compounds, to processes for obtaining them, to their uses, and also to their reduction to oligopyrroles and to the uses of the pyridazinylpyrrole and oligopyrrole compounds obtained. The invention relates in particular to the uses as medicaments, in particular for treating pathologies such as cancer, bacterial infections or parasitic infections, and also the uses in the materials, environmental, electronics and optics field.Type: ApplicationFiled: July 26, 2007Publication date: November 25, 2010Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)Inventors: Didier Max Dubreuil, Muriel Genevieve Pipelier, Jean-Paul Pradere, Hicham Bakkali, Patrice Lepape, Thierry Delaunay, Alexandra Tabatchnik
-
Publication number: 20100298336Abstract: The present invention features compounds having the Formula (Ia) and (Ib) (e.g., a compound of any of Formulas ((Ia-2)-(Ia-21)), including other tautomers, stereoisomers, E/Z stereoisomers, prodrugs, pharmaceutically acceptable salts, and compositions thereof. The invention also features methods for treating or preventing pain (e.g., neuropathic pain), inflammation, or epilepsy in a patient by administering an effective amount of a compound of Formula (Ia) or (Ib). The invention also features a method for treating or preventing pain (e.g., neuropathic pain), inflammation, or epilepsy in a patient that includes administering to a patient in need thereof an effective amount of a compound of Formula (IIa) or (IIb) (e.g., a compound of any of Formulas ((IIa-2)-(IIa-6)). The compounds described herein (e.g., a compound of Formulas (Ia), (Ib), (IIa), or (IIb)) can also be used as anticonvulsants.Type: ApplicationFiled: May 21, 2010Publication date: November 25, 2010Inventors: Giorgio Attardo, Sasmita Tripathy, Martin Gagnon
-
Publication number: 20100298267Abstract: The present application relates to novel aminopyrimidinamides, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects.Type: ApplicationFiled: February 17, 2010Publication date: November 25, 2010Applicant: Bayer CropScience AGInventors: Simon MAECHLING, Arnd Voerste, Eva-Maria Franken, Angela Becker, Ulrich Görgens, Mazen Es-Sayed, Markus Heil, Graham Holmwood, Johannes-Rudolf Jansen, Otto Schallner, Ulrich Ebbinghaus-Kintscher, Peter Lümmen, Silvia Cerezo-Galvez, Sachio Kudo, Takashi Hashihayata, Eiichi Shimojo, Teruyuki Ichihara, Masashi Ataka, Katsuhiko Shibuya
-
Patent number: 7838525Abstract: The present invention relates to certain trisubstituted aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.Type: GrantFiled: November 21, 2006Date of Patent: November 23, 2010Assignee: Arena Pharmaceuticals, Inc.Inventors: Robert M. Jones, Graem Semple, Yifeng Xiong, Young-Jun Shin, Albert S. Ren, Imelda Calderon, Beatriz Fioravanti, Jin Sun Karoline Choi, Juerg Lehmann, Marc A. Bruce
-
Publication number: 20100292205Abstract: The invention pertains to pyrimidone compounds that serve as effective GSK-3 inhibitors. The invention further relates to pharmaceutical compositions and methods comprising such pyrimidone compounds; and the use of such compounds for treating certain disorders.Type: ApplicationFiled: August 13, 2007Publication date: November 18, 2010Applicant: PFIZER INC.Inventors: Bruce A. Lefker, Michael A. Brodney, Subas M. Sakya, Bruce A. Hay, Matthew D. Wessel, Edward L. Conn
-
Patent number: 7834002Abstract: The present invention provides 4-amino-5-cyanopyrimidine derivatives of the formula: wherein R1, R2 and R3 are defined herein, or pharmaceutically acceptable salts thereof, having a safe and potent adenosine A2a receptor agonistic activity; and also provides an adenosine A2a receptor agonist, an intraocular pressure reducing agent, or a medicine for treating glaucoma, etc., which comprises the compound as an active ingredient.Type: GrantFiled: April 28, 2005Date of Patent: November 16, 2010Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Masaya Kato, Norifumi Sato, Minoru Okada, Tetsuyuki Uno, Nobuaki Ito, Yasuhiro Takeji, Hisashi Shinohara, Masahiro Fuwa
-
Publication number: 20100286158Abstract: This invention relates to dihydropyrimidinones of the formula wherein X and R1 to R7 are as defined in the description, as well as pharmaceutically acceptable salts thereof. These compounds are BACE2 inhibitors and can be used as medicaments for the treatment or prevention of diseases such as diabetes.Type: ApplicationFiled: April 30, 2010Publication date: November 11, 2010Inventors: David Banner, Hans Hilpert, Roland Humm, Harald Mauser, Alexander V. Mayweg, Fabienne Ricklin, Mark Rogers-Evans
-
Publication number: 20100273764Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.Type: ApplicationFiled: April 27, 2010Publication date: October 28, 2010Applicant: Amgen Inc.Inventors: Kristin Andrews, Yunxin Y. Bo, Shon Booker, Victor J. Cee, Noel D'Angelo, Bradley J. Herberich, Fang-Tsao Hong, Claire L.M. Jackson, Brian A. Lanman, Hongyu Liao, Longbin Liu, Nobuko Nishimura, Mark H. Norman, Liping H. Pettus, Anthony B. Reed, Adrian L. Smith, Seifu Tadesse, Nuria A. Tamayo, Bin Wu, Ryan Wurz, Kevin Yang
-
Publication number: 20100266543Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: February 9, 2010Publication date: October 21, 2010Inventors: Yao-Ling Qiu, Ce Wang, Lu Ying, Xiaowen Peng, Yat Sun Or
-
Patent number: 7816526Abstract: The present invention provides a compound represented by the formula: wherein Q represents a fused heterocyclic group, X and Y are the same or different and each represent an optionally halogenated lower alkyl group, an optionally halogenated lower alkoxy group, etc., or a salt thereof, as well as a herbicide comprising the compound or a salt thereof, which exhibits a significant effect for control of sulfonylurea herbicide-resistant weeds in paddy fields and can reduce the number of active ingredients in a combined preparation and a method of controlling sulfonylurea herbicide-resistant weeds which comprises using the same.Type: GrantFiled: January 15, 2003Date of Patent: October 19, 2010Assignee: Sumitomo Chemical Company, LimitedInventors: Yasushi Tanaka, Yukari Kajiwara, Makoto Noguchi, Takeshi Kajiwara, Takanori Tabuchi
-
Publication number: 20100261742Abstract: Novel polymorphic forms of bosentan and processes for their preparation are disclosed. Further, pharmaceutical compositions comprising said polymorphic forms and the use of said compositions in the treatment of patients suffering from endothelin receptor mediated disorders, for example, cardiovascular disorders such as hypertension, pulmonary hypertension, ischemia, vasospasm and angina pectoris are disclosed.Type: ApplicationFiled: May 8, 2008Publication date: October 14, 2010Inventors: Abhay Gaitonde, Bindu Manojkumar, Sandeep Mekde, Dattatraya Shinde, Prakash Bansode
-
Publication number: 20100258036Abstract: A monoazo pigment is represented by the general formula (1), a tautomer of the monoazopigment, and a salt or a hydrate thereof: wherein R1, P1, and Q1 each independently represents a hydrogen or a substituent, G represents the non-metallic atoms necessary to complete a 5- to 6-membered heterocyclic group, W represents a substituent capable of binding to the heterocyclic group constituted by G, t represents an integer of from 0 to 5, Het-1 represents a group selected from the aromatic heterocyclic groups represented by the general formula (2): wherein X, Y, Z, W0, W1, W2, W3, and W4 each independently represents a hydrogen or a substituent, and * shows the point of attachment to the azo linkage in the general formula (1).Type: ApplicationFiled: September 3, 2008Publication date: October 14, 2010Applicant: FUJIFILM CORPORATIONInventors: Keiichi Tateishi, Shinya Hayashi, Yoshiaki Nagata, Tomoaki Nakamura
-
Publication number: 20100256371Abstract: The present invention relates to processes for the preparation of bosentan and compounds that can be used as structurally novel intermediates for the synthesis thereof, and a pharmaceutical composition of the same.Type: ApplicationFiled: March 16, 2010Publication date: October 7, 2010Applicant: GlenmarkInventors: Roop Singh Yadav, Mubeen Ahmed Khan, Sachin Mahadeo Lad, Nikhil Rasiklal Trivedi, Sankar Arjunan, Gajendra Laxman Pitale
-
Patent number: 7807676Abstract: This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with diketo piperazine and piperadine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.Type: GrantFiled: October 23, 2007Date of Patent: October 5, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Tao Wang, John F. Kadow, Zhongxing Zhang, Zhiwei Yin, Nicholas A. Meanwell, Alicia Regueiro-Ren, Jacob Swidorski, Ying Han, David J. Carini, Lawrence G. Hamann
-
Publication number: 20100249405Abstract: The present invention relates to novel IAP inhibitor compounds of formula I:Type: ApplicationFiled: December 7, 2007Publication date: September 30, 2010Inventors: Zhuoliang Chen, Run-Ming David Wang, Ming Chen, Christopher Sean Straub, Leigh Zawel
-
Publication number: 20100249162Abstract: The present invention relates to an improved process for the preparation of bosentan. In particular it relates to a process for preparing bosentan substantially free from the dimer impurity of formula (II) and the 6-hydroxy impurity of formula (III). The invention also relates to a pharmaceutical composition comprising bosentan and its use in the treatment of endothelin-receptor mediated disorders.Type: ApplicationFiled: June 27, 2008Publication date: September 30, 2010Inventors: Abhay Gaitonde, Bindu Manojkumar, Sandeep Sonawane, Dattatrey Kokane, Sandeep Mekde, Dattatraya Shinde, Prakash Bansode
-
Publication number: 20100240636Abstract: The present invention disclosed compounds of Structural Formula (I), and enantiomer, racemic body, pharmaceutically acceptable salts, solvates or hydrates thereof, wherein variable groups are as defined within, as well as methods for preparing such compounds. The compounds are useful as PPAR? agonist, through activating PPAR-RXR heterodimers that intereacts with specific DNA response elements within promoter regions of target gene, particularly in the treatment and prevention of polycystic kidney and cancer.Type: ApplicationFiled: October 11, 2007Publication date: September 23, 2010Inventors: Jianhua Shen, Changlin Mei, Hualiang Jiang, Bin Dai, Yangliang Ye, Xishan Xiong, Jing Tang, Lili Fu
-
Publication number: 20100240892Abstract: Disclosed are electroluminescent devices that comprise organic layers that contain certain organic compounds containing one ore more pyrimidine moieties. The organic compounds containing one ore more pyrimidine moieties are suitable components of blue-emitting, durable, organo-electroluminescent layers. The electroluminescent devices may be employed for full color display panels in for example mobile phones, televisions and personal computer screens.Type: ApplicationFiled: June 7, 2010Publication date: September 23, 2010Inventors: THOMAS SCHÄFER, Patrice Bujard, Jonathan Rogers, Kristina Bardon
-
Publication number: 20100234376Abstract: The invention provides a novel class of compounds of the Formula I: in which the symbols have the meanings given in the description and claims, to pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of FGFR3 kinase.Type: ApplicationFiled: July 10, 2007Publication date: September 16, 2010Inventors: Pamela A. Albaugh, Yun He, Songchun Jiang, Pingda Ren, Xia Wang, Xing Wang, Yongping Xie
-
Publication number: 20100234405Abstract: A novel pyrimidine nucleoside derivative represented by the following formula (1) and a salt thereof, as well as a pharmaceutical composition comprising the same as an active ingredient have excellent antiviral properties and are useful as antiviral therapeutic agents: [wherein R represents a nitrogen-containing heterocyclic ring which may have any one of a C1-C3 alkyl group or a C1-C3 alkoxy group as a substituent, or a C1-C6 alkyl group which has one primary amino group as a substituent].Type: ApplicationFiled: February 15, 2007Publication date: September 16, 2010Applicant: ARIGEN PHARMACEUTICALS, INC.Inventors: Haruhiko Machida, Masaichi Yamamoto
-
Publication number: 20100216815Abstract: A series of N-substituted oxindole derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, calcium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, diabetic neuropathy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, sleep disorder, bipolar disorder and stroke, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.Type: ApplicationFiled: September 30, 2008Publication date: August 26, 2010Inventors: Joseph L. Duffy, Scott B. Hoyt, Clare London
-
Publication number: 20100216792Abstract: The invention is directed to arylpyrrolidines compounds which exhibit excellent insecticidal efficacy and which may be used as in the agrochemical field or in the field of veterinary medicine. The compounds are represented by formula (I): wherein the respective substituents are defined in the specification.Type: ApplicationFiled: October 14, 2009Publication date: August 26, 2010Applicant: Bayer CropScience AGInventors: Ulrich Görgens, Jun Mihara, Tetsuya Murata, Daiei Yamazaki, Yasushi Yoneta, Koichi Araki, Norio Sasaki, Kei Domon, Mamoru Hatazawa, Eiichi Shimojo, Teruyuki Ichihara, Masashi Ataka, Katsuhiko Shibuya
-
Publication number: 20100210467Abstract: It is intended to provide an agent for improving sugarcane Brix which increases the sugar productivity from pressed juice after harvesting and promotes ripening when applied to sugarcane and, therefore, by which a sugar yield comparable to sugarcane harvested at the best harvest season can be established even from sugarcane before reaching the harvest season, which comprises at least one member of the compounds represented by the following general formula (I) wherein A represents an oxygen atom, a sulfur atom, or a hydroxymethylene group; Y represents a carboxyl group, an alkyloxycarbonyl group, a halogenated methylsulfonylamino group or a diphenylmethylideneiminoxycarbonyl group, either in a free form or forming a salt; and R represents a halogen atom, an alkyl group, a hydroxy-, alkoxy- or alkoxyiminoalkyl group or a 4,6-dimethoxypyrimidin-2-yloxy group, or Y and R may be bonded together to form a group —C(?O)—O—CH(CH3)—.Type: ApplicationFiled: October 24, 2008Publication date: August 19, 2010Inventors: Masanori Kobayashi, Shuji Ohno, Yoshihiro Yamaji, Ryo Hanai, Jose Antonio De Souza Junior, Helio Massatoshi Tukamoto
-
Publication number: 20100204237Abstract: Compounds of Formula (1), pharmaceuticals containing the same, especially anti-HIV agents having anti viral activity, especially inhibitory activity against HIV integrase, wherein X represents either one of the following groups: (wherein, C ring is nitrogen-containing aromatic heterocyclic ring in which at least one atom in atoms neighboring the atom bound to the pyrimidine ring is unsubstituted nitrogen atom; R10 is hydrogen or lower alkyl; D ring is aryl or heteroaryl) Z1 and Z3 each is independently a single bond, O, S, S(?O) or SO2; Z2 is a single bond, lower alkylene or lower alkenylene; Ar is optionally substituted aryl or optionally substituted heteroaryl; R1 is lower alkyl, substituted lower alkyl or the like; R2 is a hydrogen atom or optionally substituted lower alkyl; or R1 and R2 may form, together with an adjacent atom, an optionally substituted heterocyclic ring, a pharmaceutically acceptable salt or a solvate thereof.Type: ApplicationFiled: April 21, 2010Publication date: August 12, 2010Inventors: Hidenori Mikamiyama, Minamo Iwata, Yoshiyuki Taoda
-
Publication number: 20100187977Abstract: Provided is an organic electroluminescent device (organic EL device) that is improved in luminous efficiency, fully secured of driving stability, and simply constructed. The EL device has a light-emitting layer disposed between an anode and a cathode stacked one upon another on a substrate and the light-emitting layer comprises a phosphorescent dopant and an indolocarbazole derivative as a host material. Examples of the indolocarbazole compounds include a compound represented by the following formula (2) or (3), wherein X is N or CH, at least one of Xs is N, and Ar1 to Ar3 each is a substituted or unsubstituted aromatic group.Type: ApplicationFiled: November 8, 2007Publication date: July 29, 2010Applicant: NIPPON STEEL CHEMICAL CO., LTD.Inventors: Takahiro Kai, Masaki Komori, Toshihiro Yamamoto
-
Publication number: 20100187505Abstract: The present invention relates to the compounds of the formula (1) and to organic electroluminescent devices, in particular blue-emitting devices, in which these compounds are used as host material or dopant in the emitting layer and/or as hole-transport material and/or as electron-transport material.Type: ApplicationFiled: April 29, 2008Publication date: July 29, 2010Inventors: Philipp Stoessel, Arne Buesing, Holger Heil
-
Publication number: 20100184978Abstract: A bipyridine compound represented by the formula (1): wherein R1, R2 and R3 each independently represent a C1-C10 alkyl group which may be substituted etc., and R4, R5, R6, R7 and R8 each independently represent a hydrogen atom etc., a transition metal complex obtained by contacting a bipyridine compound represented by the formula (1) with a compound of a transition metal belonging to Group 9, 10 or 11, and a method for production of a conjugated aromatic compound comprising reacting an aromatic compound (A) wherein one or two leaving groups are bonded to an aromatic ring with an aromatic compound (A) having the same structure as that of the above-mentioned aromatic compound (A) or an aromatic compound (B) being structurally different from the above-mentioned aromatic compound (A) and having one or two leaving groups bonded to an aromatic ring, in the presence of the transition metal complex.Type: ApplicationFiled: June 18, 2008Publication date: July 22, 2010Inventors: Taku Asaumi, Takashi Kamikawa
-
Publication number: 20100173901Abstract: The present invention relates to substituted heterocyclic compounds of Formula I: or pharmaceutically acceptable salts or N-oxides or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are histamine H4 receptor inhibitors/antagonists useful in the treatment of histamine H4 receptor-associated conditions or diseases or disorders including, for example, inflammatory diseases or disorders, pruritus, and pain.Type: ApplicationFiled: December 21, 2009Publication date: July 8, 2010Applicant: INCYTE CORPORATIONInventors: Colin Zhang, Ding-quan Qian, Jincong Zhuo, Wenqing Yao
-
Publication number: 20100160325Abstract: This invention relates to novel compounds having the formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.Type: ApplicationFiled: February 26, 2010Publication date: June 24, 2010Applicant: ASTRAZENECA ABInventors: Xiaomei Feng, Huiping Guan, Stephanos Ioannidis, Bo Peng, Mei Su, Tao Wang, Hai-Jun Zhang, Ying Kan, Bin Wang
-
Publication number: 20100141122Abstract: An OLED device including a cathode, an anode, and having therebetween a light-emitting layer and further comprising a first layer between the light-emitting layer and the cathode containing a cyclobutene compound comprising a cyclobutene nucleus substituted in the 1-position with a five- or six-membered heteroaromatic ring group containing at least one trivalent nitrogen atom; substituted in the 2-position with an aromatic ring group; and substituted with a first methylene group in the 3-position and a second methylene group in the 4-position, provided said first and second methylene groups are further disubstituted in the 1?,1?-positions and the 1?,1?-positions with independently selected aromatic groups.Type: ApplicationFiled: December 9, 2008Publication date: June 10, 2010Inventors: William J. Begley, Natasha Andrievsky
-
Publication number: 20100144043Abstract: A fluorescent sensor compound based on a perylene core is described and disclosed. The fluorescent sensor compound for detecting mercury can have a structure I: where A and A? are linking groups, B and B? are binding ligands which are selective for binding with Hg2+, and R1 through R8 are side groups. These fluorescence sensor materials are robust against photobleaching, while still providing exceptional detection sensitivity and selectivity.Type: ApplicationFiled: December 9, 2009Publication date: June 10, 2010Inventors: Ling Zang, Yanke Che
-
Publication number: 20100127616Abstract: Disclosed is an organic electroluminescent device (organic EL device) which is improved in luminous efficiency, fully secured of driving stability, and of simple constitution. Also disclosed is a compound useful for the fabrication of said organic EL device. The organic electroluminescent device comprises organic layers including a light-emitting layer disposed between an anode and a cathode which are piled one upon another on a substrate and at least one of said organic layers comprises a compound for an organic EL device represented by general formula (1). Said organic layer is preferably a light-emitting layer containing a phosphorescent dopant.Type: ApplicationFiled: March 26, 2008Publication date: May 27, 2010Applicant: NIPPON STEEL CHEMICAL CO., LTD.Inventors: Takahiro Kai, Toshihiro Yamamoto, Masanori Hotta, Junya Ogawa
-
Patent number: 7723266Abstract: The invention relates to novel substituted arylsulphonyl(thio)ureas in which A represents nitrogen or a CH grouping, Q represents oxygen or sulphur, R1 represents hydrogen, halogen or respectively optionally substituted alkyl, alkoxy, alkylthio, alkylamino, dialkylamino, cycloalkyl, cycloalkyloxy or heterocyclyloxy, R2 represents hydrogen, halogen or respectively optionally substituted alkyl, alkoxy, alkylthio, alkylamino, dialkylamino, cycloalkyl, cycloalkyloxy or heterocyclyloxy, R3 represents hydrogen or optionally substituted alkyl, R4 represents respectively optionally substituted alkyl, alkoxy, alkenyl, alkinyl, alkenyloxy, alkinyloxy, cycloalkyl, cycloalkyloxy or cycloalkylalkyl, and R5 represents hydrogen, formyl or respectively optionally substituted alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulphonyl, alkenyl, alkinyl, cycloalkyl, cycloalkylcarbonyl, cycloalkylsulphonyl or heterocyclyl, and to salts of compounds of the formula (I), except for the compound N-(4,6-dimethyl-primidin-2-yl)-N?-[2-1Type: GrantFiled: July 29, 2004Date of Patent: May 25, 2010Assignee: Bayer AktiengesellschaftInventors: Ernst Rudolf F. Gesing, Rolf Kirsten, Joachim Kluth, Klaus-Helmut Müller, Mark Wilhelm Drewes, Johannes Rudolf Jansen, Ulrich Philipp, Hans-Jochem Riebel, Otto Schallner, Markus Dollinger, Hans-Joachim Santel
-
Patent number: 7718242Abstract: A recording layer including a novel dye for a high density optical recording medium, employing short wavelength laser source with a wavelength not longer than 530 nm for recording high density information and reproduction/playback of the high density information recordings, is provided.Type: GrantFiled: February 7, 2007Date of Patent: May 18, 2010Assignee: Industrial Technology Research InstituteInventors: Ming-Chia Li, Chien-Liang Huang, An-Tze Lee, Wen-Yih Liao, Ching-Yu Hsieh, Tzuan-Ren Jeng
-
Publication number: 20100113445Abstract: The present invention relates to dianilinopyrimidine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such dianilinopyrimidine derivatives are useful in the treatment of diseases associated with inappropriate Wee1 kinase activity.Type: ApplicationFiled: March 12, 2008Publication date: May 6, 2010Inventors: Felix Deanda, JR., David Harold Drewry, Paul Reid
-
Publication number: 20100087460Abstract: The present invention discloses a series of pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: Wherein X, Z, R1, R2, R3, R4, R5, R6, R7, n and m are as defined herein. Also disclosed herein are the methods of preparation of compounds of formula (I), intermediates therefor and their utility in treating a variety of disease conditions.Type: ApplicationFiled: October 27, 2009Publication date: April 8, 2010Applicants: SANOFI-AVENTIS, MITSUBISHI TANABE PHARMA CORPORATIONInventors: Nathalie CHEREZE, Thierry GALLET, Alistair LOCHEAD, Mourad SAADY, Corinne VERONIQUE, Philippe YAICHE
-
Publication number: 20100087461Abstract: The present invention discloses a series of pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: Wherein X, Z, R1, R2, R3, R4, R5, R6, R7, n and m are as defined herein. Also disclosed herein are the methods of preparation of compounds of formula (I), intermediates therefor and their utility in treating a variety of disease conditions.Type: ApplicationFiled: October 27, 2009Publication date: April 8, 2010Applicants: SANOFI-AVENTIS, MITSUBISHI TANABE PHARMA CORPORATIONInventors: Alistair LOCHEAD, Mourad SAADY, Corinne VERONIQUE, Philippe YAICHE
-
Publication number: 20100087449Abstract: The present invention discloses a series of pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: Wherein X, Z, R1, R2, R3, R4, R5, R6, R7, n and m are as defined herein. Also disclosed herein are the methods of preparation of compounds of formula (I), intermediates therefor and their utility in treating a variety of disease conditions.Type: ApplicationFiled: October 27, 2009Publication date: April 8, 2010Applicants: SANOFI-AVENTIS, MITSUBISHI TANABE PHARMA CORPORATIONInventors: Alistair Lochead, Mourad Saady, Corinne Veronique, Philippe Yaiche